SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
SOPHiA GENETICS (Nasdaq: SOPH) has expanded its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN) in a multi-year collaboration focused on breast cancer treatment optimization. The partnership will utilize SOPHiA GENETICS's multimodal AI Factories to analyze genomics, imaging, and clinical data to generate evidence on therapy efficacy and develop AI-powered predictive models.
The collaboration aims to generate real-world evidence in Europe and North America, leveraging one of healthcare's most diverse multimodal datasets to enhance clinical decision-making and treatment outcomes. The partnership highlights SOPHiA GENETICS's capabilities in managing complex healthcare data environments through secure, compliant, and scalable real-world AI applications.
SOPHiA GENETICS (Nasdaq: SOPH) ha ampliato la sua collaborazione con AstraZeneca (LSE/STO/Nasdaq: AZN) in un progetto pluriennale volto all'ottimizzazione del trattamento del cancro al seno. La partnership sfrutterà le AI Factories multimodali di SOPHiA GENETICS per analizzare dati genomici, di imaging e clinici, al fine di produrre evidenze sull'efficacia delle terapie e sviluppare modelli predittivi basati sull'intelligenza artificiale.
La collaborazione punta a generare evidenze reali in Europa e Nord America, utilizzando uno dei dataset multimodali più diversificati nel settore sanitario per migliorare le decisioni cliniche e i risultati terapeutici. Questa partnership sottolinea le capacità di SOPHiA GENETICS nella gestione di ambienti dati sanitari complessi tramite applicazioni AI real-world sicure, conformi e scalabili.
SOPHiA GENETICS (Nasdaq: SOPH) ha ampliado su colaboración con AstraZeneca (LSE/STO/Nasdaq: AZN) en un acuerdo plurianual centrado en la optimización del tratamiento del cáncer de mama. La asociación utilizará las Fábricas de IA multimodales de SOPHiA GENETICS para analizar datos genómicos, de imagen y clínicos, con el objetivo de generar evidencia sobre la eficacia de las terapias y desarrollar modelos predictivos impulsados por IA.
La colaboración busca generar evidencia del mundo real en Europa y Norteamérica, aprovechando uno de los conjuntos de datos multimodales más diversos en el ámbito sanitario para mejorar la toma de decisiones clínicas y los resultados del tratamiento. La asociación destaca la capacidad de SOPHiA GENETICS para gestionar entornos de datos sanitarios complejos mediante aplicaciones de IA del mundo real seguras, conformes y escalables.
SOPHiA GENETICS (나스닥: SOPH)는 AstraZeneca (LSE/STO/나스닥: AZN)와 유방암 치료 최적화를 위한 다년간 협력을 확대했습니다. 이 파트너십은 SOPHiA GENETICS의 다중 모달 AI 팩토리를 활용하여 유전체학, 영상 및 임상 데이터를 분석하고 치료 효과에 대한 증거를 생성하며 AI 기반 예측 모델을 개발할 예정입니다.
이번 협력은 유럽과 북미에서 실제 데이터를 활용한 증거를 생성하는 것을 목표로 하며, 의료 분야에서 가장 다양한 다중 모달 데이터셋 중 하나를 활용해 임상 의사결정과 치료 결과를 향상시키고자 합니다. 이 파트너십은 복잡한 의료 데이터 환경을 안전하고 규정을 준수하며 확장 가능한 실제 AI 애플리케이션으로 관리하는 SOPHiA GENETICS의 역량을 강조합니다.
SOPHiA GENETICS (Nasdaq : SOPH) a étendu son partenariat avec AstraZeneca (LSE/STO/Nasdaq : AZN) dans le cadre d'une collaboration pluriannuelle axée sur l'optimisation du traitement du cancer du sein. Ce partenariat utilisera les usines d'IA multimodales de SOPHiA GENETICS pour analyser les données génomiques, d'imagerie et cliniques afin de générer des preuves sur l'efficacité des thérapies et de développer des modèles prédictifs basés sur l'IA.
Cette collaboration vise à produire des preuves issues du monde réel en Europe et en Amérique du Nord, en exploitant l'un des ensembles de données multimodales les plus diversifiés dans le domaine de la santé pour améliorer la prise de décision clinique et les résultats des traitements. Ce partenariat met en lumière les capacités de SOPHiA GENETICS à gérer des environnements de données de santé complexes grâce à des applications d'IA réelles sécurisées, conformes et évolutives.
SOPHiA GENETICS (Nasdaq: SOPH) hat seine Partnerschaft mit AstraZeneca (LSE/STO/Nasdaq: AZN) in einer mehrjährigen Zusammenarbeit zur Optimierung der Brustkrebsbehandlung ausgeweitet. Die Partnerschaft wird die multimodalen KI-Fabriken von SOPHiA GENETICS nutzen, um Genomik-, Bildgebungs- und klinische Daten zu analysieren, um Evidenz zur Wirksamkeit von Therapien zu generieren und KI-gestützte Vorhersagemodelle zu entwickeln.
Die Zusammenarbeit zielt darauf ab, in Europa und Nordamerika Real-World-Evidenz zu generieren und dabei einen der vielfältigsten multimodalen Datensätze im Gesundheitswesen zu nutzen, um klinische Entscheidungen und Behandlungsergebnisse zu verbessern. Die Partnerschaft unterstreicht die Fähigkeiten von SOPHiA GENETICS, komplexe Gesundheitsdatenumgebungen durch sichere, konforme und skalierbare Real-World-KI-Anwendungen zu managen.
- Strategic expansion of partnership with major pharmaceutical company AstraZeneca
- Access to diverse multimodal healthcare datasets for AI model development
- Geographic expansion across Europe and North America for real-world evidence generation
- Reinforcement of SOPHiA GENETICS's position as a trusted AI technology partner in healthcare
- None.
Insights
SOPHiA GENETICS expands its commercial reach through a multi-year AI collaboration with AstraZeneca, strengthening its market position in precision oncology.
This expanded collaboration between SOPHiA GENETICS and AstraZeneca represents a significant commercial validation of SOPHiA's AI platform capabilities in the oncology space. The multi-year partnership will leverage SOPHiA's multimodal AI Factories to analyze complex datasets spanning genomics, imaging, and clinical information specifically for breast cancer applications.
The strategic value here is twofold: First, SOPHiA gains a stable revenue stream through this extended engagement with a pharmaceutical giant. Second, the collaboration enhances SOPHiA's competitive positioning in the growing AI-driven precision medicine market, which is projected to see substantial growth as healthcare increasingly embraces artificial intelligence for clinical decision support.
What makes this partnership particularly valuable is its focus on real-world evidence generation across Europe and North America. This approach addresses a critical industry need for data that reflects actual clinical practice outside controlled trial environments. By helping AstraZeneca understand treatment efficacy drivers in breast cancer through federated analytics (analyzing data where it resides without moving sensitive patient information), SOPHiA strengthens its position as a trusted intermediary in the healthcare AI ecosystem.
The development of a potential bespoke predictive model for breast cancer treatment optimization could also lead to proprietary clinical decision support tools with commercial applications beyond this single partnership, potentially creating additional revenue opportunities in the future.
Derived from cutting-edge computing protocols and trained on one of the most diverse multimodal datasets in healthcare, SOPHiA GENETICS's AI Factories offer powerful predictive insights for assessing patient prognosis and treatment response. AstraZeneca will utilize SOPHiA GENETICS's AI Factories to analyze multimodal healthcare data — including genomics, imaging, and clinical data — and generate AI-powered insights to help optimize breast cancer outcomes. The companies will also collaborate on real-world evidence generation in
"We are proud to deepen our partnership with AstraZeneca through this significant new initiative, which highlights the growing demand for secure, compliant, and scalable real-world AI applications," said Ross Muken, President of SOPHiA GENETICS. "Our platform is purpose-built to manage complex healthcare data environments, and this collaboration reinforces our shared commitment to driving better patient outcomes through trusted, federated analytics powered by data and AI."
"At AstraZeneca, a core component of our AI strategy has been rooted in the deployment of frontier AI solutions across oncology clinical development," said Jorge Reis-Filho, Chief AI and Data Scientist, AstraZeneca. "Fine tuning and augmenting our models with multimodal data – including our own data and the data that will be generated as part of this collaboration – is helping us to generate a more holistic understanding of disease biology and biomarkers to tailor the most effective treatment to patients living with cancer."
This collaboration reinforces SOPHiA GENETICS' position as a trusted technology partner and underlines its commitment to advancing global health through federated data analytics and artificial intelligence.
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-expands-collaboration-with-astrazeneca-using-ai-to-improve-breast-cancer-patient-outcomes-302521027.html
SOURCE SOPHiA GENETICS
FAQ
What is the purpose of SOPHiA GENETICS's expanded collaboration with AstraZeneca?
How will SOPHiA GENETICS's AI Factories benefit breast cancer treatment?
What types of data will be analyzed in the SOPH and AstraZeneca collaboration?
Where will SOPHiA GENETICS and AstraZeneca conduct their real-world evidence generation?
What makes SOPHiA GENETICS's AI Factories unique in healthcare?
